BioNxt Solutions Inc.

WHO'M
ai
Digital Profiler. Simply click the AI button
CUSIP
090974106
SEDOL
N/A
CIK
N/A
bionxt.com
LEI:
©
FIGI: BBG00PVP57Y6
BNXT
BioNxt Solutions Inc.
GICS: - · Sector: - · Sub-Sector: -
NAME
BioNxt Solutions Inc.
ISIN
CA0909741062
TICKER
BNXT
MIC
XCNQ
REUTERS
BNXT.CD
BLOOMBERG
BNXT CN
BUILD THEMEFOLIO SHARE IDEAS DISCUSS
LEVERAGE INVEST
EN 728x90
Financial Intelligence
360° iHub Crowd iFeed ATH Tracker Index Tracker ETF TF Spicy2 X-Billboard
FOR INVESTORS
FOR TRADERS
Securities Trading Warrants

The X-News Explorer is the ultimate source of information for investors with an affinity for the stock market who want to get a quick and convenient overview of the current news situation of a listed company. Various newswire services are available here. If a news alert is displayed, you will find company news that may be of interest to you. This service is provided by AccessWire.

Tue, 29.10.2024       BioNxt Solutions
CA0909741062

BioNxt Solutions Inc. („BioNxt" oder das „Unternehmen") (CSE: BNXT / OTCQB: BNXTF / FWB: BXT) freut sich bekannt zu geben, dass das Unternehmen ein Nationalisierungsverfahren für die Einreichung einer Patentfamilie für die sublinguale Verabreichung von Krebsmedikamenten zur Behandlung von neurodegenerativen Autoimmunerkrankungen...
Read More
BioNxt Solutions
Technical Analysis Termsheet Terminal
Permalink
Mon, 07.10.2024       BioNxt Solutions
CA0909741062

VANCOUVER, BC / ACCESSWIRE / October 7, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT) is pleased to announce that Terry Lynch has joined the BioNxt team as a capital markets advisor. Mr. Lynch brings decades of start-up and emerging growth capital markets experience in the resource ...
Read More
BioNxt Solutions
Technical Analysis Termsheet Terminal
Permalink
Thu, 26.09.2024       BioNxt Solutions
CA0909741062

VANCOUVER, BC / ACCESSWIRE / September 26, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT) is pleased to provide an update on its flagship sublingual Cladribine drug formulation program for the treatment of Multiple Sclerosis ("MS"), broad sublingual patent application for t...
Read More
BioNxt Solutions
Technical Analysis Termsheet Terminal
Permalink
Thu, 15.08.2024       BioNxt Solutions
CA0909741062

BioNxt Solutions Inc. („BioNxt" oder das „Unternehmen") (CSE: BNXT) (OTCQB: BNXTF) (FWB: BXT) freut sich bekannt zu geben, dass es eine unverbindliche Absichtserklärung mit dem in Deutschland ansässigen internationalen Auftragsforschungs-, Entwicklungs- und Produktionsunternehmen Gen-Plus GmbH & Co KG („Gen-Plus"), eine...
Read More
BioNxt Solutions
Technical Analysis Termsheet Terminal
Permalink
We are different
OPEN FINANCIAL
DATA & KNOWLEDGE HUB
We make the difference
Information on product placements